<PAGE> 1
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended December 31, 1996 Commission File Number 0-16594
MEDICAL TECHNOLOGY SYSTEMS, INC.
- -------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 59-2740462
-------- ----------
(State or other jurisdiction of (I.R.S. Employer ID Number)
incorporation or organization)
12920 Automobile Boulevard, Clearwater, Florida 34622
------------------------------------------------------
(address of principal executive offices)
Registrant's telephone number, including area code: (813) 576-6311
--------------
Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 of 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days. YES X NO
---- ----
Indicate by check mark whether the Registrant has filed all documents
and reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. YES X NO ___________
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
Class Outstanding at December 31, 1996
----- --------------------------------
Common Stock, $.01 par value 5,903,788
Preferred Stock, $.0001 par value 6,500,000
<PAGE> 2
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
INDEX
<TABLE>
<CAPTION>
Page
----
<S> <C>
Part I - Financial Information
- ------------------------------
Item 1. Financial Statements
Consolidated Balance Sheets -
March 31, 1996 and December 31,1996 . . . . . . . . . . . . . . . . . . . . . . . . 1
Consolidated Statements of Operations -
Three months and Nine months ended December 31, 1996 and 1995 . . . . . . . . . . . 2
Consolidated Statements of Changes in Stockholders' Equity (Deficit) -
Nine months ended December 31, 1996 . . . . . . . . . . . . . . . . . . . . . . . . 3
Consolidated Statements of Cash Flow -
Nine months ended December 31, 1996 and 1995 . . . . . . . . . . . . . . . . . . . . 4
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . 5 - 9
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations . . . . . . . . . . . . . . . . . . . . . . . . 10 - 12
Part II - Other Information
- ---------------------------
Item 4. Submission of Matters to a Vote of Security-Holders . . . . . . . . . . . . . . . . . . 13
Item 6. Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Signature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
</TABLE>
i
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In Thousands)
<TABLE>
<CAPTION>
ASSETS
December 31, March 31,
1996 1996
------------ ----------
(Unaudited)
<S> <C> <C>
Current Assets:
Cash.......................................................... $ 1,076 $ 965
Accounts Receivable, Net...................................... 3,225 3,260
Income Taxes.................................................. 0 880
Inventories................................................... 2,418 2,445
Prepaids and Other............................................ 134 264
Advances to Affiliates........................................ 173 -0-
--------- ---------
Total Current Assets.......................................... 7,026 7,814
Property and Equipment, Net............................................ 4,156 4,917
Other Assets:
Goodwill, Net................................................. 916 971
Product Development and Related Software, Net................. 391 170
Patents, Net.................................................. 527 565
Other, Net.................................................... 220 232
---------- ---------
Total Other Assets............................................ 2,054 1,938
---------- ---------
Total Assets........................................................... $ 13,236 $ 14,669
========== =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Current Maturities of Long-Term Debt.......................... $ 282 $ 168
Accounts Payable-Trade and Accrued Liabilities................ 1,556 2,240
---------- ---------
Total Current Liabilities..................................... 1,838 2,408
Liabilities Subject to Compromise...................................... -0- 30,457
Long-Term Debt, Less Current Maturities................................ 26,572 350
---------- ---------
Total Liabilities...................................................... 28,410 33,215
---------- ---------
Stockholders' Equity (Deficit):
Voting Preferred Stock........................................ 1 1
Common Stock.................................................. 59 55
Capital in Excess of Par Value................................ 8,430 8,320
Retained Earnings (Deficit)................................... (23,333) (26,591)
Less: Treasury Stock.......................................... (331) (331)
-------- ---------
Total Stockholders' Equity (Deficit) ........................ (15,174) (18,546)
-------- ---------
Total Liabilities and Stockholders' Equity ............................ $ 13,236 $ 14,669
========== =========
a) Liabilities Subject to Compromise consist of the following:
Secured Debt.................................................. $ -0- $ 28,158
Trade and Other Miscellaneous Claims ......................... -0- 2,299
---------- ---------
$ -0- $ 30,457
========== =========
</TABLE>
The accompanying notes are an integral part of these financial statements.
1
<PAGE> 4
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands; except Earnings Per Share Amounts)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
December 31, December 31,
1996 1995 1996 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
Revenue:
Net Sales and Services . . . . . . . . . . . . . . . . $ 4,624 $ 4,084 $ 14,264 $ 12,340
Costs and Expenses:
Cost of Sales . . . . . . . . . . . . . . . . . . . . 2,433 2,332 7,773 6,913
Selling, General and Administrative . . . . . . . . . 1,847 2,572 4,685 7,382
Loss on Early Retirement of Fixed Assets . . . . . . . -0- -0- -0- 3,000
Project and Product Development . . . . . . . . . . . -0- -0- -0- 1,574
Loss on Inventory Revaluation . . . . . . . . . . . . -0- -0- -0- 513
Depreciation and Amortization . . . . . . . . . . . . 343 313 1,023 1,017
Interest, Net . . . . . . . . . . . . . . . . . . . . (23) 621 (33) 1,799
-------- -------- -------- --------
Total Costs and Expenses . . . . . . . . . 4,600 5,838 13,448 22,198
-------- -------- -------- --------
Income (Loss) from Continuing Operations Before Income
Taxes and Extraordinary Gain . . . . . . . . . . . . . 24 (1,754) 816 (9,858)
Income Tax (Benefit) . . . . . . . . . . . . . . . . . -0- -0- -0- (353)
-------- -------- -------- --------
Income (Loss) from Continuing Operations Before
Extraordinary Gain . . . . . . . . . . . . . . . . . . 24 (1,754) 816 (9,505)
Income (Loss) from Discontinued Operations, Net of
Income Tax . . . . . . . . . . . . . . . . . . . . . . -0- (675) -0- (5,108)
-------- -------- -------- --------
Net Income (Loss) Before Extraordinary Gain . . . . . . . $ 24 $ (2,429) $ 816 $(14,613)
Extraordinary Gain - Adjustment of debt upon emergence
from Bankruptcy . . . . . . . . . . . . . . . . . . . -0- -0- 2,441 -0-
-------- -------- -------- --------
Net Income (Loss) . . . . . . . . . . . . . . . . . . . $ 24 $ (2,429) $ 3,257 $(14,613)
======== ======== ======== ========
Net Earnings (Loss) per Common Share (Primary and Fully
Diluted)
Continuing Operations . . . . . . . . . . . . . . . . $ .00 $ (.44) $ .14 $ (2.38)
Discontinued Operations . . . . . . . . . . . . . . . .00 (.17) .00 (1.28)
Extraordinary Gain . . . . . . . . . . . . . . . . . . .00 .00 .43 .00
-------- -------- -------- --------
Net Income (Loss) . . . . . . . . . . . . . . . . . . $ .00 $ (.61) $ .57 $ (3.66)
======== ======== ======== ========
Weighted average Common Shares outstanding . . . . . . . 5,904 3,993 5,677 3,993
======== ======== ======== ========
</TABLE>
The accompanying notes are an integral part of these financial statements.
2
<PAGE> 5
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
NINE MONTHS ENDED DECEMBER 31, 1996
(In Thousands Except Share Data)
(Unaudited)
<TABLE>
<CAPTION>
COMMON STOCK
---------------------------------------------------------------------------------------
Number $.01 Capital in Retained
of Par Excess of Earnings Treasury
Shares Value Par Value (Deficit) Stock Total
------ ----- ------------ ------------- ---------- ------
<S> <C> <C> <C> <C> <C> <C>
Balance, March 31,1996 . . . 5,485,335 $ 55 $8,320 $(26,591) $(331) $(18,547)
Net Income for Three Months
Ended June 30, 1996 . . . . 363 363
----------------------------------------------------------------------------------------------
Balance, June 30, 1996 . . . 5,485,335 $ 55 $8,320 $(26,228) $(331) $(18,184)
Stock Issued . . . . . . . . 458,453 4 110 114
Net Income for Three Months
Ended September 30, 1996 . . 2,871 2,871
----------------------------------------------------------------------------------------------
Balance, September 30, 1996 . 5,943,788 $ 59 $8,430 $(23,357) $(331) $(15,199)
----------------------------------------------------------------------------------------------
Net Income for Three Months
Ended December 31, 1996 . . 24 24
----------------------------------------------------------------------------------------------
Balance, December 31, 1996 . 5,943,788 $ 59 $8,430 $(23,333) $(331) $(15,175)
==============================================================================================
</TABLE>
<TABLE>
<CAPTION>
VOTING PREFERRED STOCK
------------------------------------------------------------
Number $.0001
of Par
Shares Value
------ ------
<S> <C> <C> <C>
Balance, March 31, 1996 6,500,000 $ 1 $ 1
--------- ----- ---------
Balance, September 30, 1996 6,500,000 $ 1 $ 1
--------- ----- ----------
Balance, December 31, 1996 6,500,000 $ 1 $ 1
--------- ----- ----------
Total Stockholders' Equity (Deficit),
December 31, 1996 $ (15,174)
============
</TABLE>
The accompanying notes are an integral part of these financial statements.
3
<PAGE> 6
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW
(In Thousands)
(Unaudited)
<TABLE>
<CAPTION>
Nine Months Ended
December 31,
1996 1995
---- ----
<S> <C> <C>
OPERATING ACTIVITIES
Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3,257 $ (9,505)
Adjustments to Reconcile Net Income (Loss) to Net Cash
Provided (Used) by Operating Activities:
Depreciation and Amortization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,023 1,017
Loss on Disposal of Fixed Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . -0- 3,000
Project and Product Development Expenses, Net . . . . . . . . . . . . . . . . . . . . . -0- 1,174
Extraordinary Gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2,441) -0-
(Increase) Decrease in:
Accounts Receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 20
Income Taxes Receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880 -0-
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 (95)
Prepaid Expenses and Other Assets . . . . . . . . . . . . . . . . . . . . . . . . . (31) (63)
Increase (Decrease) in:
Accounts Payable and Other Accrued Liabilities . . . . . . . . . . . . . . . . . . . (688) 2,422
Income Taxes Payable and Deferred Taxes . . . . . . . . . . . . . . . . . . . . . . -0- 177
------- --------
Total Adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,195) 7,652
------- --------
Net Cash Provided (Used) by Continuing Operations . . . . . . . . . . . . . . . . . . . . 2,062 (1,853)
------- --------
Net Cash Provided by Discontinued Operations . . . . . . . . . . . . . . . . . . . . . . -0- 327
------- --------
INVESTING ACTIVITIES
Expended for Property and Equipment . . . . . . . . . . . . . . . . . . . . . . . . . (136) (781)
Expended for Software Development . . . . . . . . . . . . . . . . . . . . . . . . . . -0- (242)
Expended for Product Development . . . . . . . . . . . . . . . . . . . . . . . . . . . (249) (325)
Expended for Patents and Other Assets . . . . . . . . . . . . . . . . . . . . . . . . -0- (1,301)
------- --------
Net Cash Used by Investing Activities . . . . . . . . . . . . . . . . . . . . . . . . (385) (2,649)
------- --------
FINANCING ACTIVITIES
Payments on Notes Payable, Long-Term Debt . . . . . . . . . . . . . . . . . . . . . . (1,680) (20,202)
Net Proceeds from Line of Credit . . . . . . . . . . . . . . . . . . . . . . . . . . . -0- 24,109
Issuance of Common Stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 5
------- --------
Net cash (Used) Provided by Financing Activities . . . . . . . . . . . . . . . . . . . (1,566) 3,912
------- --------
NET INCREASE (DECREASE) IN CASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 (263)
CASH AT BEGINNING OF PERIOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 965 613
------- --------
CASH AT END OF PERIOD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,076 $ 350
======= ========
</TABLE>
The accompanying notes are an integral part of these financial statements.
4
<PAGE> 7
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1996
(UNAUDITED)
NOTE A - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting principles
for interim financial information and with the instructions to Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and notes required by generally accepted accounting principles for
complete financial statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for a fair
presentation have been included. Operating results for the nine month period
ended December 31, 1996 are not necessarily indicative of the results that may
be expected for the year ended March 31, 1997. The unaudited condensed
consolidated financial statements should be read in conjunction with the
consolidated financial statements and notes thereto included in the Company's
annual report on Form 10-K/A for the year ended March 31, 1996.
NOTE B - PRODUCT LINE INFORMATION
The following table illustrates the revenue contributed by the
Company's two product lines for the three and nine months ended December 31,
1996:
<TABLE>
<CAPTION>
Revenue by Product Line
Three Months Ended Nine Months Ended
December 31, December 31,
1996 1995 1996 1995
---- ---- ----- ----
<S> <C> <C> <C> <C>
Medication Dispensing Systems $3,069 $2,795 $9,689 $8,398
Clinical Laboratory Services 1,555 1,289 4,575 3,942
------ ------ ------ ------
$4,624 $4,084 $14,264 $12,340
====== ====== ======= =======
</TABLE>
NOTE C - CHAPTER 11 REORGANIZATION MATTERS
During the fourth quarter of fiscal 1996, the Company filed voluntary
petitions for relief under Chapter 11 ("Chapter 11") of Title 11 of the United
States Bankruptcy Code in the Middle District of Florida, Tampa Division (the
"Bankruptcy Court") for four of its subsidiaries (MTS debtors). On September
4, 1996, plans of reorganization for the MTS debtors were confirmed by the
Bankruptcy Court. As part of the plans of reorganization for the MTS debtors,
certain liabilities have been compromised by creditors of the Company as
follows:
Secured Claims (Bank) - Bank notes payable, line of credit, accrued
interest and other charges and expenses, in the amount of approximately
$28,000,000 have been combined and restructured into two separate promissory
notes (Plan Note I and Plan Note II).
Plan Note I, in the stated principal amount of approximately
$27,000,000, provides for a portion of the principal amount, $15,000,000, to be
due and payable as follows:
a) Interest at the rate of 7.5% for a period of two (2) years
ending September 1, 1998.
b) Installments of principal and interest at the rate of 7.5%
payable monthly for a period of ten (10) years ending September 1, 2006. At
which time, the then outstanding principal amount is due and payable in full.
The monthly installments of principal and interest are calculated based on the
principal amount amortized in level monthly payments over twenty (20) years.
5
<PAGE> 8
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1996
(UNAUDITED)
NOTE C - CHAPTER 11 REORGANIZATION MATTERS, CONTINUED
Plan Note I further provides that the net sales proceeds from the sale
of one of the MTS debtors (Vangard Labs, Inc.) will be paid to the bank. In
addition, certain other mandatory prepayments of the stated principal amount
are required upon the occurrence of a capital transaction in which any of the
Company's subsidiaries are sold, as well as upon the receipt of any proceeds
resulting from certain causes of action commenced by the Company. Plan Note I
also provides that the full stated principal amount shall be due and payable
upon the occurrence of specified major events of default.
Plan Note II, in the stated principal amount of $1,000,000 provided
for payment of $750,000 on or about the date of the confirmation of the plans
of reorganization of the MTS debtors. The Company made the payment of $750,000
on or about September 5, 1996 and in accordance with the terms of Plan Note II,
the stated principal amount was deemed fully satisfied. The repayment of both
Plan Notes I and II have been personally guaranteed by Todd E. Siegel.
As noted above, there exists the possibility that additional
prepayments and payments will be made towards the bank debt. At present the
quantification of these amounts, if any, cannot be determined. The amount of
debt forgiveness currently recognizable cannot be determined until any
additional payments, if any, are known and it is determined to be highly
unlikely that certain events of default, as defined in the amended and restated
loan agreement, will occur. In addition, no amounts of interest expense will
be recorded until it is determined that the principal payments, the additional
prepayments and the interest payments in the aggregate exceed the carrying
value of the Company's bank debt.
Unsecured Claims (Trade Creditors) - The holders of approximately
$2,300,000 of trade and other miscellaneous claims elected to receive payment
of their claims under one of the three options which were provided for in the
plans of reorganization. The Company has determined that the net present value
of the amounts, discounted at an annual rate of 10%, to be paid to these
creditors is $407,000. The first payment to the unsecured creditors is
approximately $250,000, and is due in March of 1997. The Company has placed
sufficient funds in escrow with its bankruptcy counsel to satisfy this payment.
Other payments to the unsecured creditors are due annually commencing one year
from the date on which the plans of reorganization were confirmed.
Unsecured Claims (Other) - In March 1995, the Company entered into an
agreement relating to the acquisition of certain clinical laboratory accounts
for its Medical Technology Laboratories, Inc. subsidiary. The Company reached a
compromise with the seller which reduced the acquisition indebtedness to
$500,000. The net present value of this indebtedness, discounted at an annual
rate of 10%, is approximately $286,000.
The adjustment of unsecured claims resulted in a reduction of the
amount of these claims in the amount of $2,441,000. This amount has been
classified as an extraordinary gain in the Company's consolidated statement of
operations and statement of cash flow for the nine months ended December 31,
1996.
In addition to the plans of reorganization, the Company has instituted
cost reduction measures which have contributed significantly to the profitable
results of operation for the nine months ended December 31, 1996. The plans of
reorganization were prepared based upon estimated levels of revenue and
expenses which management determined to be reasonable. Based upon these
estimates, management believes that the repayment obligations which are part of
the plans of reorganization can be met, however, there can be no assurances
that this will occur.
NOTE D - DISCONTINUED OPERATIONS
As part of a corporate restructuring strategy, the Company plans to concentrate
its resources on its medication card business and the medication dispensing
technology products which have been developed and are presently marketable.
Although the clinical diagnostic laboratory business has been identified as a
non-core business, its operations are a source of cash to support future debt
obligations of the Company. The Company's generic drug repackaging subsidiary,
Vangard Labs, Inc. whose production operations were suspended on January 3,
1996 and subsequently filed a voluntary petition under Chapter 11 of the United
States Bankruptcy Code in the Middle District of Florida on February 22,
1996, will be divested, and as a result, has been treated as a discontinued
6
<PAGE> 9
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1996
(UNAUDITED)
NOTE D - DISCONTINUED OPERATIONS, CONTINUED
operation. A liquidating plan of reorganization for Vangard Labs, Inc. was
confirmed by the Bankruptcy Court on September 4, 1996. The liquidating plan
provides for Vangard Labs, Inc. to be sold and the proceeds from the sale will
be paid to the Company's bank in accordance with Plan Note I referred to in
Note B.
Attempts to sell Vangard Labs, Inc. have been unsuccessful to date.
Certain operating expenses have continued to be incurred by Vangard Labs, Inc.
in order to maintain a minimum staff of personnel and perform stability tests
on the drugs which are held in inventory. These ongoing stability tests are
required by the FDA. The Company, in cooperation with its bank, have provided
funds to pay the operating expenses. As of December 31, 1996, the amount owed
to the Company by Vangard Labs, Inc. is $173,332 and is included in the
Company's consolidated balance sheet as advances to affiliates. In the event
of a sale of Vangard Labs, Inc. the Company expects to recover the full amount
of these advances.
In addition, the Glasgow Pharmaceutical Corporation (GPC) joint
venture with Creighton Pharmaceutical Corporation, a wholly owned subsidiary of
Sandoz Pharmaceuticals, Inc. is considered a discontinued operation primarily
because of its dependence upon Vangard production capabilities.
The net assets and operating results of the discontinued operations
were segregated in the consolidated financial statements for all periods
presented.
NOTE E - INVENTORIES
The components of inventory consist of the following:
<TABLE>
<CAPTION>
December 31, March 31,
1996 1996
------------ ----------
(In Thousands)
<S> <C> <C>
Raw Materials $ 870 $ 661
Finished Good and Work in Progress 1,548 1,784
--------- ---------
$ 2,418 $ 2,445
========= =========
</TABLE>
Inventories are stated at the lower of cost (first-in, first-out) or
market.
NOTE F - EARNINGS PER SHARE
The Company calculates its fully diluted earnings per share under the
modified treasury stock method. The utilization of the modified treasury stock
method for the nine months ended December 31, 1996 is antidilutive. As such,
the Company has presented its fully diluted earnings per share based upon the
weighted average number of shares outstanding.
7
<PAGE> 10
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1996
(UNAUDITED)
NOTE G - LONG-TERM DEBT
Long-term debt consists of the following:
<TABLE>
<CAPTION>
December 31, March 31,
1996 1996
----- ----
(In Thousands)
<S> <C> <C>
Note payable; interest at bank prime plus 1/2%; or LIBOR rate plus
2 1/4%; payable $93,000 per month plus interest, maturing
September, 1998 (see Plan Note I and II) . . . . . . . . . . . . . . . $ 0 $ 10,398
Bank line of credit, interest at bank prime plus 1/2%, or LIBOR
rate plus 2%; interest payable monthly; principal maturing
September, 1996 (see Plan Note I and II). . . . . . . . . . . . . . . . 0 16,862
Notes Payable Bank (Plan Note I and II as described in Note C) . . . . . . 26,141 0
Seller Financing Under Tampa Pathology Acquisition Agreement, face
value of $500,000 discounted at 10%, with variable monthly payments
until satisfied (see Note C) . . . . . . . . . . . . . . . . . . . . . . 286 871
Other Notes and Agreements; interest and principal payable monthly and
annual at various amounts through June 1998 . . . . . . . . . . . . . . . 427 545
---------- ---------
Total Long-Term Debt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,854 28,676
Less Current Portion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . (282) (168)
Subject to Compromise . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 (28,158)
---------- ---------
LONG-TERM DEBT DUE AFTER 1 YEAR . . . . . . . . . . . . . . . . . . . . . . . $ 26,572 $ 350
========== =========
</TABLE>
The following is a schedule by year of the principal payments required
on these notes payable and long-term debts as of December 31, 1996:
<TABLE>
<CAPTION>
(In Thousands)
<S> <C>
1997 . . . . . . . . . . . . . . . . . . . . . $ 282
1998 . . . . . . . . . . . . . . . . . . . . . $ 160
</TABLE>
The above bank loans and line of credit are collateralized by the
Company's accounts receivables, inventory, equipment and intangibles. The
prime rate at December 31, 1996 was 8.25%.
NOTE H - UNCERTAINTIES
The accompanying condensed consolidated financial statements have been
prepared on the basis that the Company will continue as a going concern. As
discussed in the Company's Form 10-K/A for the fiscal year ended March 31,
1996, certain conditions raised substantial doubt as to the Company's ability
to continue as a going concern.
8
<PAGE> 11
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1996
(UNAUDITED)
NOTE H - UNCERTAINTIES, CONTINUED
On September 4, 1996 the Company's major subsidiaries emerged from
bankruptcy. In addition, the Company was successful in restructuring its
indebtedness with its principal secured lender. These events have contributed
to the results of operation for the nine months ended December 31, 1996,
however, the ability of the Company to continue as a going concern is dependent
on, among other things, future profitable operations, ability to generate
sufficient cash flow from operations and the ability to obtain financing
sources to meet future obligations. The plans of reorganization, which have
been approved by the bankruptcy court, provide for a significant reduction in
the amount of indebtedness which the Company owed to its secured lender and its
other creditors. This reduction in indebtedness, in conjunction with a return
to profitable operations, as well as continued cooperation from the suppliers
of material and services has allowed the Company to operate efficiently to
date.
NOTE I - SUPPLEMENTAL CASH FLOW INFORMATION
<TABLE>
<CAPTION>
Nine Months Ended
December 31,
1996 1995
---- ----
<S> <C> <C>
Cash Paid:
Interest . . . . . . . . . . . . . . . . . . . . . . . . $ -0- $ 1,388
Income taxes (net of refund) . . . . . . . . . . . . . . (880) -0-
Non-Cash Financing and Investing Activities:
Restructured Debt:
Carrying value before reorganization . . . . . . . . . . $ 3,133 $ -0-
Forgiveness (see Note B) . . . . . . . . . . . . . . . . 2,441 -0-
--------- --------
Adjusted carrying value . . . . . . . . . . . . . . . . $ 692 $ -0-
========= ========
</TABLE>
NOTE J - INCOME TAXES
As discussed in Note B, on September 4, 1996 the Chapter 11 plans of
reorganization for four MTS debtors were approved by the Bankruptcy Court.
This resulted in an approximate $2.4 million reduction in unsecured claims
during the nine months ended December 31, 1996. The related income has been
excluded from taxable income pursuant to Internal Revenue Code (IRC) Section
108 through the reduction of certain tax attributes including net operating
losses. The current taxability of the potential debt forgiveness related to
the secured bank claim is under review by management. The Company currently
believes that such amounts, if any, would also be excluded from taxable income
under IRC Section 108, again through a reduction of tax attributes including
net operating losses.
The remaining taxable income for the quarter and the nine months ended
December 31, 1996 has been substantially offset by the existing net operating
loss carryforwards.
At December 31, 1996, the Company has net operating losses available
of approximately $20,000,000, subject to any reductions related to the
resolution of the above matter (see paragraph one). A tax benefit has not been
recorded for these losses since it is not yet more likely than not that these
benefits will be realized by reducing future taxable income.
9
<PAGE> 12
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
This report contains certain forward-looking statements regarding
future financial condition and results of operations and the Company's business
operations. The words "except," "estimate," "anticipate," "predict" and
similar expressions are intended to identify forward-looking statements. Such
statements involve risks, uncertainties and assumptions, including industry and
economic conditions, customer action and other factors discussed in this report
and in the Company's other filings with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual outcomes may vary materially
from those indicated.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
RESULTS OF OPERATIONS
Three Months Ended December 31, 1996 and 1995
Net sales for the three months ended December 31, 1996 increased 13.3%
from $4,084,000 to $4,624,000 during the same period the previous year. The
increase in net sales resulted primarily from increases in revenues of 20.6% in
the Company's clinical laboratory services business segment which resulted from
an increase in the number of physicians serviced. Revenues in the Company's
medication dispensing business segment increased 9.8% in the third fiscal
quarter of 1997 compared to the same quarter of 1996. This increase is
attributable to increased sales of both disposable medication punch cards by
MTS Packaging Systems, Inc. as well as medication dispensing systems sold by
Medication Management Systems, Inc.
Cost of sales for the three months ended December 31, 1996 increased
4.3% from $2,332,000 to $2,433,000 during the same period the prior year. The
increase in cost of sales resulted primarily from an increase in total revenue.
Cost of sales as a percentage of sales decreased to 52.6% from 57.1% the prior
year. The decrease was primarily due to a decrease in cost of sales in the
medication dispensing business segment. Cost of sales as a percentage of sales
for this segment was 48.3% compared to 60.2% the prior year. The decrease
resulted from incremental gross profit margin contributed by additional
medication dispensing system installations and disposable punch card sales.
Cost of sales as a percentage of sales increased in the third quarter of fiscal
1997 to 61.1% from 50.3% the prior year in the clinical laboratory segment.
Reductions in Medicare reimbursement policies for services performed
contributed to the decrease in gross margin for this segment.
Selling, general and administrative expenses decreased $725,000
(28.1%) for the three months ended December 31, 1996 as compared to the prior
year. The decrease resulted from cost reduction measures which the Company
instituted during its Chapter 11 reorganization. These cost reductions
included significant reductions in sales and administrative personnel in the
medication dispensing business segment and administrative personnel and
services in the holding company. SG&A expenses decreased $525,000 in the
medication dispensing business segment, $126,000 in the holding company and
$74,000 in the clinical laboratory segment.
Depreciation and amortization expense increased $30,000 (9.6%) for the
three months ended December 31, 1996. The increase resulted from a reduction
in the estimated useful lives of property and equipment.
Interest expense for the three months ended December 31, 1996 was
eliminated as a result of the modification and restructuring of the bank debt.
Until such time that the Company's principal, interest and other cash payments
exceed the carrying value of the bank debt, no interest expense will be
recognized (see Note B to the financial statements). Accordingly, all cash
payments of interest will be accounted for as reductions of the carrying amount
of the debt. As a result, interest payments of $275,000, which were payable by
the Company during the three months ended December 31, 1996, have been applied
toward the principal amount of the debt.
Net income from continuing operations and before extraordinary items
for the three months ended December 31, 1996 was $24,000 compared to a loss of
$1,754,000 in the prior year. The increase in net income resulted from
increases in revenue and gross profits, and reductions in selling, general and
administrative expenses, and interest expense
10
<PAGE> 13
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
Nine Months Ended December 31, 1996 and 1995
Net sales for the nine months ended December 31, 1996 increased 15.6%
from $12,340,000 to $14,264,000 during the same period the previous year. The
increase in net sales resulted primarily from increased sales of MTS Packaging,
Inc. products, through wholesale distribution, increased installations of
pharmacy systems by Performance Pharmacy Systems, Inc. and an increase in the
number of physicians serviced by Medical Technology Laboratories, Inc.
Revenues for the medication dispensing systems business segment increased 15.3%
in fiscal 1997 compared to the previous year. Revenues for the clinical
laboratory services segment increased 16.1% in fiscal 1997 compared to the
previous year.
Cost of sales for the nine months ended December 31, 1996, increased
$860,000 (12.4%) compared to the previous year. The increase resulted
primarily from the increase in revenues in each business segment. Cost of
sales as a percentage of sales was 54.5% in fiscal 1997 compared to 56.0% the
prior year. Cost of sales as a percentage of sales in the medication
dispensing systems business segment decreased to 52.4% in fiscal 1997 from
56.2% the prior year. The decrease resulted from incremental gross profit
margin contributed by additional medication dispensing system installations and
disposable punch card sales. Cost of sales as a percentage of sales increased
to 58.8% in 1997 from 55.6% the prior year in the clinical laboratory segment
primarily as a result of reductions in Medicare reimbursement policies for
services performed.
Selling, general and administrative expenses decreased $2,697,000
(36.5%) for the nine months ended December 31, 1996 compared to the previous
year. The decrease resulted from cost reduction measures the Company
instituted during its Chapter 11 reorganization. SG&A expenses decreased
$1,449,000 in the medication dispensing business segment, $1,073,000 in the
holding company and $175,000 in the clinical laboratory segment.
Depreciation and amortization expense decreased $16,000 (.6%) for the
nine months ended December 31, 1996 compared to the previous year.
Interest expense was eliminated during the nine months ended December
31, 1996 compared to $1,799,000 the previous year. The reasons for the
elimination of interest expense during the nine months ended December 31, 1996
are substantially the same as those outlined in the comparative quarterly
discussions.
Net income from continuing operations and before extraordinary items
was $816,000 for the nine months ended December 31, 1996 compared to a net loss
of $9,505,000 the previous year. The reasons for the increase in net income
from continuing operations for the nine months ended December 31, 1996 are
substantially the same as those outlined in the comparative quarterly
discussions.
Extraordinary income for the nine months ended December 31, 1996 was
$2,441,000 which represents the adjustment of the unsecured claims held by the
creditors of the Company's subsidiaries pursuant to the plans of reorganization
approved by the bankruptcy court.
LIQUIDITY AND CAPITAL RESOURCES
Cash provided from continuing operations for the nine months ended
December 31, 1996 was $2,062,000 compared to $1,853,000 used during the
previous year. Cash was provided from continuing operations primarily as a
result of profitable operations and the receipt of income tax refunds.
Investing activities utilized $385,000 during the nine months ended
December 31, 1996 compared to $2,649,000 the previous year. The decrease
resulted from the fact that the Company significantly reduced its capital
equipment and project development activities as compared to the prior year.
Financing activities used $1,566,000 during the nine months ended
December 31, 1996 compared to providing $3,912,000 the previous year. The
Company made certain payments amounting to approximately $450,000 to its
secured lender during the first three months of fiscal 1997 as part of the
Chapter 11 reorganization of its principal subsidiaries. These payments were
authorized by the Bankruptcy Court as adequate protection for the secured
lender pursuant to a continuing order which allowed the
11
<PAGE> 14
MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
Company to utilize the collateral as a Debtor in Possession under the
jurisdiction of the Bankruptcy Court. In addition, the Company paid $750,000
on or about September 4, 1996 pursuant to its restructured loan agreement with
its secured lender which is discussed in Note B included in the Company's
condensed consolidated financial statements contained herein. In addition, the
Company began to pay interest on its outstanding bank indebtedness in October
1996. These payments have reduced the carrying value of the Company's bank
debt as outlined in Note C to the condensed consolidated financial statements.
The Company had working capital of $5,188,000 as of December 31, 1996
and has no other source of working capital other than that which is generated
from operations.
Included in the Company's working capital is $250,000 which has been
placed in escrow with the Company's legal counsel to be utilized for the first
payment to unsecured creditors, claims and other administrative costs pursuant
to the plans of reorganization of the Company's principal subsidiaries.
Note C to the condensed consolidated financial statements outlines the
Company's obligations pursuant to the plans of reorganization which were
approved by the bankruptcy court. The Company's short-term and long-term
liquidity is dependent on its ability to generate cash flow from operations.
Accounts receivable and inventory levels are not expected to change
significantly based upon the Company's current level of operation. There are
no major capital equipment expenditures anticipated during this fiscal year.
The accompanying condensed consolidated financial statements have been
prepared on the basis that the Company will continue as a going concern. As
discussed in the Company's Form 10-K/A for the fiscal year ended March 31,
1996, certain conditions raised substantial doubt as to the Company's ability
to continue as a going concern.
On September 4, 1996 the Company's major subsidiaries emerged from
bankruptcy. In addition, the Company was successful in restructuring its
indebtedness with its principal secured lender. These events have contributed
to the results of operation for the nine months ended December 31, 1996,
however, the ability of the Company to continue as a going concern is dependent
on, among other things, future profitable operations, ability to generate
sufficient cash flow from operations and the ability to obtain financing
sources to meet future obligations.
12
<PAGE> 15
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS.
The Annual Meeting of the Shareholders of the Company was held on
November 21, 1996. Messrs. Todd E. Siegel, David Kazarian, Michael Conroy, and
John Stanton were elected directors of the Company for one year terms with
4,319,307 shares of Common Stock and 6,500,000 shares of Voting Preferred Stock
voting in favor, 4,228 shares of Common Stock and zero shares of Voting
Preferred Stock voting against, and 178,705 shares of Common Stock and zero
shares of Voting Preferred Stock abstaining.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(A) 27 - Financial data schedule as of December 31, 1996 (for SEC use
only) (filed herewith).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Quarterly Report to be signed on its behalf
by the undersigned, thereunto duly authorized, in the County of Pinellas, State
of Florida, on the 13th day of February, 1997.
MEDICAL TECHNOLOGY SYSTEMS, INC.
By: /s/ Michael P. Conroy
----------------------------------
Michael P. Conroy
Vice President & Chief Financial
Officer
13
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED FINANCIAL STATEMENTS OF MEDICAL TECHNOLOGY SYSTEMS INC. FOR THE NINE
MONTHS ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> MAR-31-1997
<PERIOD-START> APR-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 1,076
<SECURITIES> 0
<RECEIVABLES> 4,222
<ALLOWANCES> 997
<INVENTORY> 2,418
<CURRENT-ASSETS> 7,026
<PP&E> 8,207
<DEPRECIATION> 4,051
<TOTAL-ASSETS> 13,236
<CURRENT-LIABILITIES> 1,838
<BONDS> 0
0
1
<COMMON> 55
<OTHER-SE> 8,430
<TOTAL-LIABILITY-AND-EQUITY> 13,236
<SALES> 14,264
<TOTAL-REVENUES> 14,264
<CGS> 7,773
<TOTAL-COSTS> 13,448
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 816
<INCOME-TAX> 0
<INCOME-CONTINUING> 816
<DISCONTINUED> 0
<EXTRAORDINARY> 2,441
<CHANGES> 0
<NET-INCOME> 3,257
<EPS-PRIMARY> .57
<EPS-DILUTED> .57
</TABLE>
